Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will report its next earnings on Feb 1 – Feb 6 (Est.). The company reported the earnings of $1.23/Share in the last quarter where the estimated EPS by analysts was $1.17/share. The difference between the expected and actual EPS was $0.06/share, which represents an Earnings surprise of 5.1%.
Many analysts are providing their Estimated Earnings analysis for Alexion Pharmaceuticals, Inc. and for the current quarter 19 analysts have projected that the stock could give an Average Earnings estimate of $1.27/share. These analysts have also projected a Low Estimate of $1.16/share and a High Estimate of $1.46/share.
In case of Revenue Estimates, 17 analysts have provided their consensus Average Revenue Estimates for Alexion Pharmaceuticals, Inc. as 838.46 Million. According to these analysts, the Low Revenue Estimate for Alexion Pharmaceuticals, Inc. is 763 Million and the High Revenue Estimate is 887.43 Million. The company had Year Ago Sales of 700.87 Million.
These analysts also forecasted Growth Estimates for the Current Quarter for ALXN to be 12.4%. They are projecting Next Quarter growth of 32.3%. For the next 5 years, Alexion Pharmaceuticals, Inc. is expecting Growth of 18.18% per annum, whereas in the past 5 years the growth was 28.57% per annum.
Some buy side analysts are also providing their Analysis on Alexion Pharmaceuticals, Inc., where 6 analysts have rated the stock as Strong buy, 10 analysts have given a Buy signal, 5 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
When it comes to the Analysis of a Stock, Price Target plays a vital role. 19 Analysts reported that the Price Target for Alexion Pharmaceuticals, Inc. might touch $211 high while the Average Price Target and Low price Target is $169.21 and $120 respectively.
To analyze a stock, one should look for Upgrades and Downgrades of a stock. Alexion Pharmaceuticals, Inc. got Initiated on 3-Nov-16 where investment firm Deutsche Bank Initiated the stock to Buy.
Alexion Pharmaceuticals, Inc. closed its last trading session at $119.38 with the gain of 5.2%. The Market Capitalization of the company stands at 28.16 Billion. The Company has 52-week high of $193.45 and 52-week low of $110.56. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 2.54% where SMA50 and SMA200 are 1.62% and -5.89% respectively. The Company Touched its 52-Week High on Dec 31, 2015 and 52-Week Low on Jun 24, 2016.
The Relative Volume of the company is 1.57 and Average Volume (3 months) is 2.09 million. Alexion Pharmaceuticals, Inc. P/E (price to earnings) ratio is 77.19 and Forward P/E ratio of 22.32.
The company shows its Return on Assets (ROA) value of 2.8%. The Return on Equity (ROE) value stands at 4.5%. While it’s Return on Investment (ROI) value is 1.6%.
While looking at the Stock’s Performance, Alexion Pharmaceuticals, Inc. currently shows a Weekly Performance of 6.72%, where Monthly Performance is -7.38%, Quarterly performance is -2.05%, 6 Months performance is -17.75% and yearly performance percentage is -29.62%. Year to Date performance value (YTD perf) value is -34.16%. The Stock currently has a Weekly Volatility of 3.84% and Monthly Volatility of 5.60%.